Maxim lowered the firm's price target on Research Solutions to $5 from $6 and keeps a Buy rating on the shares. The company's revenue was below estimates and consensus due to churn in B2C and declines in Transactions revenue, while adjusted EBITDA was in line with consensus and beat Maxim estimate due to cost controls and continued margin expansion, the analyst tells investors in a research note.
